<scp>EML4</scp>‐<scp>ALK</scp>‐Positive Ovarian Cancer With Intracranial Metastasis Responds to Lorlatinib: A Case Report and Literature Review
We report a case showing that lorlatinib is effective in treating EML4-ALK-positive low-grade serous ovarian cancer (LGSO) with intracranial metastasis. This may be the first clinical evidence of LGSO benefit from ALK inhibitors, to provide evidence for the use of ALK inhibitors in more ovarian cancer patients with EML4-ALK fusion and promoting new ideas for the study of EML4-ALK targets in ovarian cancer.
Authors
- Huang Tang (ORCID: https://orcid.org/0000-0003-1268-8458)
- Zhiyong Yu (ORCID: https://orcid.org/0000-0002-6780-7875)
- Shun‐Rong Zhang (ORCID: https://orcid.org/0000-0002-1946-3166)
- Xiaoming Zheng
- Qin Li (ORCID: https://orcid.org/0000-0001-8822-3433)
- Tongze Cai (ORCID: https://orcid.org/0009-0000-8677-6309)
- Jianlong Zhou
- Chanjuan Li
Institutions
- The First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine (CN)
- Guangxi University of Chinese Medicine (CN)
Publication Details
- Journal
- Clinical Case Reports
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1002/ccr3.70043
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Guangxi University